MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila (Barcelona, Spain)

Meeting: MDS Virtual Congress 2021

Abstract Number: 473

Keywords: Neuromelanin, Parkinson’s, Vesicle monamine transporter(VMAT2)

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will decrease cytosolic dopamine that can convert to neuromelanin. This approach should slow down the intracellular buildup of neuromelanin that occurs with age and thus prevent, delay or attenuate PD pathology.

Background: In Parkinson’s disease (PD), there is a preferential degeneration of neurons that contain the pigment neuromelanin, especially dopaminergic neurons of the substantia nigra (SN), the loss of which leads to classical motor PD symptoms. We recently developed the first rodent model of human-like neuromelanin (NM) production based on the viral vector-mediated nigral expression of melanin-producing enzyme tyrosinase (AAV-hTyr). This has revealed that neuromelanin can trigger PD pathology when accumulated above a specific pathogenic threshold (1).

Method: Adult male Sprague-Dawley rats received single unilateral stereotaxic co-injections of AAV-hTyr and AAV-VMAT2 immediately above the SN. Control animals received equivalent amounts of either AAV-hTyr or AAV-VMAT2, separately. At selected times post-injection animals were assessed for motor asymmetry and their brains processed for histological and UPLC analyses.

Results: VMAT2 overexpression in hTyr-expressing rats reduced intracellular neuromelanin to levels below its pathogenic threshold by lowering the production of dopamine-oxidized neuromelanin precursors. In this regard, animals with VMAT2 overexpression exhibited lowered levels of oxidized dopamine and significant reductions in intracellular NM levels. Remarkably, reduction of intracellular neuromelanin levels was associated with an attenuation of PD-like motor deficits and nigrostriatal denervation in these animals. VMAT2 overexpression also restored early dopaminergic deficits that precede cell death and reduced the presence of NM-derived cellular debris and neuronophagic events.

Conclusion: The results presented herein demonstrate the feasibility and therapeutic potential of modulating intracellular neuromelanin levels in vivo by VMAT2 overexpression. 

Part of this abstract has been presented in Brain Conference 2021 (4-5 March) and AD/PD 2021 (9-14 March).

References: Carballo-Carbajal I, Laguna A, et al. Nature Communications (2019).

To cite this abstract in AMA style:

J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila. VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/vmat2-overexpression-reduces-intracellular-neuromelanin-levels-and-attenuates-parkinson-like-pathology-in-neuromelanin-producing-parkinsonian-rats/. Accessed July 11, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/vmat2-overexpression-reduces-intracellular-neuromelanin-levels-and-attenuates-parkinson-like-pathology-in-neuromelanin-producing-parkinsonian-rats/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley